Table 1 Relationship between ISL1 expression and clinicopathological features in patients with gastric cancer
Clinicopathological features | ISL1 expression | P-value | |
|---|---|---|---|
Negative (%) | Positive (%) | ||
Gender | |||
Male | 65 (46.1%) | 76 (53.9%) | 0.413 |
Female | 27 (49.1%) | 28 (50.9%) | |
Age, year | |||
≤60 | 48 (51.5%) | 46 (48.9%) | 0.167 |
>60 | 44 (43.1%) | 58 (56.9%) | |
Primary tumor location | |||
Non-cardia | 77 (49.4%) | 79 (50.6%) | 0.122 |
Cardia | 15 (37.5%) | 25 (62.5%) | |
Tumor size (cm) | |||
≤5 | 58 (45.6%) | 67 (54.4%) | 0.479 |
>5 | 34 (49.3%) | 37 (50.7%) | |
Lauren | |||
Intestinal/mixed | 61 (63.9%) | 36 (36.1%) | 0.001 |
Diffuse | 22 (24.7%) | 67 (75.3%) | |
Mix | 6 (85.7%) | 1 (14.35%) | |
Vascular invasion | |||
Absent | 61 (74.4%) | 21 (25.6%) | 0.001 |
Present | 30 (26.8%) | 82 (773.24%) | |
Histological grade | |||
Poor | 69 (65.7%) | 36 (34.3%) | 0.001 |
Well-moderate | 22 (24.4%) | 68 (75.6%) | |
Depth of invasion | |||
T1 + T2 | 40 (80.8%) | 10 (19.2%) | 0.001 |
T3 + T4 | 52 (34.7%) | 94 (65.3%) | |
Lymph-node metastasis | |||
No | 26 (65%) | 14 (35%) | 0.007 |
Yes | 65 (41.9%) | 90 (58.1%) | |
Distant metastasis | |||
M0 | 90 (50.8%) | 87 (49.2%) | 0.001 |
M1 | 2 (10.5%) | 17 (89.5%) | |
TNM stage | |||
I | 15 (78.9%) | 4 (21.1%) | 0.000 |
II | 18 (48.6%) | 19 (51.4%) | |
III | 57 (47.1%) | 64 (52.9%) | |
IV | 2 (10.5%) | 17 (89.55%) | |
